NASDAQ: VINC - Vincerx Pharma, Inc.

Yield per half year: -96.36%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Vincerx Pharma, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Vincerx Pharma, Inc.

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc.

more details
was founded in 2019 is based in Palo Alto, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-05-27
ISIN US92731L1061
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://vincerx.com
Цена ао 0.6026
Change price per day: 0% (0.275)
Change price per week: -0.2177% (0.2756)
Change price per month: -66.83% (0.829)
Change price per 3 month: -91.01% (3.06)
Change price per half year: -96.36% (7.56)
Change price per year: -71.06% (0.9502)
Change price per 3 year: -90.98% (3.05)
Change price per year to date: -93.36% (4.14)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 3.67 5
P/E 0 0
EV/EBITDA -0.1588 0
Total: 3.13

Efficiency

Title Value Grade
ROA, % -229.38 0
ROE, % -431.29 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0795 10
Total: 9.4

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 194.05 10
Yield EPS, % 676.72 10
Total: 8
More

Institutions Volume Share, %
Goldman Sachs Group Inc 1709656 7.98
Sage Rhino Capital LLC 1703413 7.95
Long Focus Capital Management, LLC 1098753 5.13
Bank of America Corporation 1082863 5.06
Rock Springs Capital Management, LP 891719 4.16
Vanguard Group Inc 513420 2.4
Kingdon Capital Management LLC 385000 1.8
Rubric Capital Management LP 354377 1.65
Point72 Asset Management, L.P. 344827 1.61
ExodusPoint Capital Management, LP 324119 1.51



Head Job title Payment Year of birth
Dr. Ahmed M. Hamdy M.D. Co-Founder, Chairman & CEO 657.54k 1965 (60 years)
Dr. Raquel E. Izumi Ph.D. Co-Founder, President, COO, Secretary & Director 591.54k 1970 (55 years)
Mr. Alexander A. Seelenberger M.B.A. Chief Financial Officer 491.69k 1979 (46 years)
Mr. Tom C. Thomas J.D. Founder, General Counsel & Chief Legal Officer 444.14k 1960 (65 years)
Dr. John C. Byrd M.D. Founder & Chairman of Scientific Advisory Board N/A
Dr. Hans-Georg Lerchen Ph.D. Chief Scientific Officer N/A
Ms. Gabriela Jairala Vice President of Investor Relations & Corporate Communications and Chief of Staff N/A
Ms. Melissa Merrick SPHR Senior Director of People & Culture and Head of Human Resource N/A
Dr. Beatrix Stelte-Ludwig Ph.D. Executive Chief Development Officer N/A
Ms. Karen Quarford M.B.A. Vice President of Quality Operations & Compliance

Address: United States, Palo Alto. CA, 260 Sheridan Avenue - open in Google maps, open in Yandex maps
Website: https://vincerx.com